AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 21527667 — intervention group
Group type: EXPERIMENTAL
Intervention: Inflection point between steady-state lactate and rising lactate (INFL)
Number of subjects: 20
Study 21527667 — intervention group
Group type: EXPERIMENTAL
Intervention: Ventilation-based predictions in hot condition after acclimation
Number of subjects: 20
Study 21527667 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood-based predictions in both environments after acclimation
Number of subjects: 20
Study 18458204 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction of catecholamine depletion (CD) by oral administration of alpha‐methylparatyrosine
Number of subjects: 28
Study 18458204 — intervention group
Group type: COMPARATOR
Intervention: Sham depletion using identical capsules containing hydrous lactose
Number of subjects: 28
Study 18458204 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction of catecholamine depletion (CD)
Number of subjects: 28
Study 17064580 — intervention group
Group type: EXPERIMENTAL
Intervention: Autotransfusion of washed red blood cells during CPB
Number of subjects: 32
Study 15071276 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic implantable cardioverter defibrillator (ICD) therapy
Number of subjects: 207
Study 15071276 — intervention group
Group type: COMPARATOR
Intervention: Optimized medical therapy (ACE inhibitors, beta-blockers, aldosterone antagonists)
Number of subjects: 207
Study 15071276 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic ICD therapy
Number of subjects: 207
Study 15071276 — intervention group
Group type: EXPERIMENTAL
Intervention: MACAS study findings
Number of subjects: 207
Study 10486880 — intervention group
Group type: EXPERIMENTAL
Intervention: rhIL-3
Number of subjects: 12
Study 10486880 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 8799518 — intervention group
Group type: EXPERIMENTAL
Intervention: Loading dose of 50 micrograms kg‐1 of diamorphine
Number of subjects: 19
Study 8799518 — intervention group
Group type: EXPERIMENTAL
Intervention: Loading dose of 200 micrograms kg‐1 of diamorphine
Number of subjects: 19
Study 8799518 — intervention group
Group type: EXPERIMENTAL
Intervention: M3G formation clearance
Number of subjects: 19
Study 8799518 — intervention group
Group type: EXPERIMENTAL
Intervention: M6G formation clearance
Number of subjects: 19
Study 8799518 — intervention group
Group type: EXPERIMENTAL
Intervention: M3G metabolite clearance
Number of subjects: 19
Study 8799518 — intervention group
Group type: EXPERIMENTAL
Intervention: M6G metabolite clearance
Number of subjects: 19
Study 8799518 — intervention group
Group type: EXPERIMENTAL
Intervention: M3G: morphine steady-state plasma concentration ratio
Number of subjects: 19
Study 8799518 — intervention group
Group type: EXPERIMENTAL
Intervention: M6G: morphine steady-state plasma concentration ratio
Number of subjects: 19
Study 2262216 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 12
Study 2262216 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 377932 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol 80 mg
Number of subjects: 11
Study 377932 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol 160 mg
Number of subjects: 11
Study 377932 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (both doses)
Number of subjects: 11
Study 377932 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 31899037 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy diet (HD; n=19)
Number of subjects: 40
Study 31899037 — intervention group
Group type: COMPARATOR
Intervention: Typical Western diet (WD; n=21)
Number of subjects: 40
Study 30770034 — intervention group
Group type: EXPERIMENTAL
Intervention: Calmer treatment, n = 5
Number of subjects: 10
Study 30770034 — intervention group
Group type: COMPARATOR
Intervention: Standard care (facilitated tucking), n = 5
Number of subjects: 10
Study 26615376 — intervention group
Group type: COMPARATOR
Intervention: 6 mg subcutaneous sumatriptan
Number of subjects: 37
Study 26615376 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg/Kg intravenous valproate
Number of subjects: 37
Study 24890527 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional testing (exercise electrocardiogram, stress nuclear imaging, or stress echocardiogram)
Number of subjects: 10000
Study 24890527 — intervention group
Group type: COMPARATOR
Intervention: Anatomical testing with ≥64‐slice multidetector coronary computed tomographic angiography
Number of subjects: 10000
Study 22495786 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral alcohol (1 g/kg) administration before ART
Number of subjects: 15
Study 22495786 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol area under the curve in untreated HIV disease
Number of subjects: 15
Study 22495786 — intervention group
Group type: EXPERIMENTAL
Intervention: C(max) in untreated HIV disease
Number of subjects: 15
Study 22495786 — intervention group
Group type: EXPERIMENTAL
Intervention: C(min) in untreated HIV disease
Number of subjects: 15
Study 22495786 — intervention group
Group type: COMPARATOR
Intervention: Post-ART alcohol administration
Number of subjects: 15
Study 20623224 — intervention group
Group type: COMPARATOR
Intervention: Bilateral superficial cervical block with isotonic saline (group A; n = 56)
Number of subjects: 162
Study 20623224 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.5% (group B; n = 52)
Number of subjects: 162
Study 20623224 — intervention group
Group type: EXPERIMENTAL
Intervention: Levobupivacaine 0.5% (group C; n = 54)
Number of subjects: 162
Study 17983379 — intervention group
Group type: EXPERIMENTAL
Intervention: Pholcodine exposure
Number of subjects: 17
Study 17983379 — intervention group
Group type: COMPARATOR
Intervention: Guaifenesin exposure
Number of subjects: 17
Study 15860531 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoxia (P(ET,O2) from 100 to 50 mmHg)
Number of subjects: 18
Study 15860531 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypocapnia (voluntary hyperventilation with P(ET,O2) clamped at 100 and 50 mmHg)
Number of subjects: 18
Study 15860531 — intervention group
Group type: EXPERIMENTAL
Intervention: Normoxic hypocapnia
Number of subjects: 18
Study 15860531 — intervention group
Group type: COMPARATOR
Intervention: Comparison with sea-level residents
Number of subjects: 18
Study 12201614 — intervention group
Group type: EXPERIMENTAL
Intervention: General exercise
Number of subjects: 77
Study 12201614 — intervention group
Group type: EXPERIMENTAL
Intervention: McKenzie treatment
Number of subjects: 77
Study 12201614 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 77
Study 9456999 — intervention group
Group type: EXPERIMENTAL
Intervention: Preterm IAI cases
Number of subjects: 610
Study 9456999 — intervention group
Group type: COMPARATOR
Intervention: Term IAI cases
Number of subjects: 610
Study 9456999 — intervention group
Group type: EXPERIMENTAL
Intervention: Preterm IAI management
Number of subjects: 610
Study 9456999 — intervention group
Group type: EXPERIMENTAL
Intervention: Preterm IAI compared with preterm births without IAI
Number of subjects: 610
Study 7621214 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical 2% lidocaine
Number of subjects: 54
Study 7621214 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 54
Study 3344936 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunotherapy with Cladosporium herbarum
Number of subjects: 22
Study 31667835 — intervention group
Group type: EXPERIMENTAL
Intervention: Occiput posterior position
Number of subjects: 838
Study 31667835 — intervention group
Group type: EXPERIMENTAL
Intervention: Occiput transverse position
Number of subjects: 838
Study 31667835 — intervention group
Group type: EXPERIMENTAL
Intervention: Attempted assisted vaginal rotational delivery for occiput posterior babies
Number of subjects: 838
Study 31667835 — intervention group
Group type: EXPERIMENTAL
Intervention: Attempted assisted vaginal rotational delivery for occiput transverse babies
Number of subjects: 838
Study 28780222 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct Anterior Approach (DAA)
Number of subjects: 46
Study 28780222 — intervention group
Group type: COMPARATOR
Intervention: Posterolateral Approach (PLA)
Number of subjects: 46
Study 26188020 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral antioxidant cocktail (AOC)
Number of subjects: 16
Study 26188020 — intervention group
Group type: COMPARATOR
Intervention: Control conditions
Number of subjects: 16
Study 23107171 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiphasic injection protocol (protocol II) with 89 mL Ioversol
Number of subjects: 30
Study 23107171 — intervention group
Group type: COMPARATOR
Intervention: Standard uniphasic injection protocol (protocol I) with 100 mL Ioversol
Number of subjects: 30
Study 23107171 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiphasic injection protocol (protocol II)
Number of subjects: 30
Study 23107171 — intervention group
Group type: COMPARATOR
Intervention: Standard uniphasic injection protocol (protocol I)
Number of subjects: 30
Study 23107171 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiphasic injection technique
Number of subjects: 30
Study 21969502 — intervention group
Group type: COMPARATOR
Intervention: Gemcitabine alone (1,000 mg/m(2)/wk for weeks 1 to 6, followed by 1 week rest, then for 3 of 4 weeks)
Number of subjects: 74
Study 21969502 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine plus radiotherapy (600 mg/m(2)/wk for weeks 1 to 5, then 4 weeks later 1,000 mg/m(2) for 3 of 4 weeks plus radiotherapy starting on day 1, 1.8 Gy/Fx for total of 50.4 Gy)
Number of subjects: 74
Study 18335584 — intervention group
Group type: EXPERIMENTAL
Intervention: Inflamed tooth and implant sites
Number of subjects: 220
Study 18335584 — intervention group
Group type: EXPERIMENTAL
Intervention: Inflamed immediately loaded (IL) sites
Number of subjects: 220
Study 18335584 — intervention group
Group type: EXPERIMENTAL
Intervention: Gingival index
Number of subjects: 220
Study 21266734 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoxia group (Hyp-Ex)
Number of subjects: 14
Study 21266734 — intervention group
Group type: COMPARATOR
Intervention: Normoxia group (Norm-Ex)
Number of subjects: 14
Study 15589194 — intervention group
Group type: EXPERIMENTAL
Intervention: Reward trials
Number of subjects: 11
Study 15589194 — intervention group
Group type: EXPERIMENTAL
Intervention: Penalty trials
Number of subjects: 11
Study 15589194 — intervention group
Group type: COMPARATOR
Intervention: Neutral trials
Number of subjects: 11
Study 15589194 — intervention group
Group type: EXPERIMENTAL
Intervention: Reward conditioning
Number of subjects: 11
Study 15589194 — intervention group
Group type: EXPERIMENTAL
Intervention: Penalty conditioning
Number of subjects: 11
Study 11575539 — intervention group
Group type: EXPERIMENTAL
Intervention: Succinylcholine
Number of subjects: 6
Study 11575539 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisatracurium
Number of subjects: 6
Study 11575539 — intervention group
Group type: EXPERIMENTAL
Intervention: Atracurium
Number of subjects: 6
Study 11575539 — intervention group
Group type: EXPERIMENTAL
Intervention: Mivacurium
Number of subjects: 6
Study 11575539 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancuronium
Number of subjects: 6
Study 11575539 — intervention group
Group type: EXPERIMENTAL
Intervention: Vecuronium
Number of subjects: 6
Study 11575539 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium
Number of subjects: 6
Study 11575539 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapacuronium
Number of subjects: 6
Study 9609978 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelets from PSS patients
Number of subjects: 7
Study 9609978 — intervention group
Group type: COMPARATOR
Intervention: Platelets from healthy controls (HC)
Number of subjects: 7
Study 9609978 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelets from both PSS patients and HC
Number of subjects: 7
Study 9609978 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelets from PSS patients and HC
Number of subjects: 7
Study 7821319 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral amiodarone (single loading dose of 25.7 +/- 0.9 mg.kg-1 body weight)
Number of subjects: 45
Study 7821319 — intervention group
Group type: COMPARATOR
Intervention: Intravenous amiodarone (bolus infusion of 3-5 mg.kg-1 over 30 min, followed by continuous infusion of 10-15 mg.kg-1 for 24 h)
Number of subjects: 45
Study 3209830 — intervention group
Group type: EXPERIMENTAL
Intervention: Augmentin
Number of subjects: 40
Study 3209830 — intervention group
Group type: COMPARATOR
Intervention: Triple antibiotic therapy (penicillin-gentamicin-metronidazole)
Number of subjects: 40
Study 30225762 — intervention group
Group type: EXPERIMENTAL
Intervention: Religious psychotherapy emphasizing the importance of prayers (reading prayers 15 and 23 of the SahifehSajjadiyeh book at the beginning of treatment sessions)
Number of subjects: 0
Study 30225762 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 0
Study 30361399 — intervention group
Group type: EXPERIMENTAL
Intervention: Cooral intraoral cooling device
Number of subjects: 180
Study 30361399 — intervention group
Group type: COMPARATOR
Intervention: Ice cooling
Number of subjects: 180
Study 26421385 — intervention group
Group type: EXPERIMENTAL
Intervention: MTX and ω‐3 fatty acids (1000 mg/d)
Number of subjects: 70
Study 26421385 — intervention group
Group type: COMPARATOR
Intervention: MTX and placebo
Number of subjects: 70
Study 24503554 — intervention group
Group type: EXPERIMENTAL
Intervention: 4D echo‐planar J‐resolved spectroscopic imaging
Number of subjects: 20
Study 22805060 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine (amphetamine administration)
Number of subjects: 2
Study 22805060 — intervention group
Group type: COMPARATOR
Intervention: Control (healthy subjects)
Number of subjects: 2
Study 20818716 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma filtration (twice weekly in Weeks 1, 2, 4, 7, and 10)
Number of subjects: 20
Study 20818716 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma filtration
Number of subjects: 20
Study 20818716 — intervention group
Group type: COMPARATOR
Intervention: Control (methylprednisolone IV pulses only)
Number of subjects: 20
Study 17666475 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 ng/kg Escherichia coli endotoxin (LPS)
Number of subjects: 10
Study 17666475 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 15172848 — intervention group
Group type: EXPERIMENTAL
Intervention: Chorionic Villus Sampling (CVS)
Number of subjects: 3775
Study 15172848 — intervention group
Group type: COMPARATOR
Intervention: Amniocentesis
Number of subjects: 3775
Study 11437398 — intervention group
Group type: COMPARATOR
Intervention: Chlorambucil (CB): 10 mg daily for 6 weeks, followed by a 2‐week interval, with 3 subsequent 2‐week treatment periods at the same dose, separated by 2‐week intervals
Number of subjects: 204
Study 11437398 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorambucil (CB) given concurrently with interferon (IFN) at a dose of 3 x 10(6) units thrice weekly, subcutaneously, throughout the 18‐week treatment period
Number of subjects: 204
Study 11437398 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance IFN at the same dose and schedule as initial treatment
Number of subjects: 204
Study 9488619 — intervention group
Group type: EXPERIMENTAL
Intervention: Clodronate 1600 mg daily
Number of subjects: 536
Study 9488619 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 536
Study 7865162 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual target selection paradigm with randomized series of target, nontarget and novel visual stimuli.
Number of subjects: 96
Study 3046878 — intervention group
Group type: EXPERIMENTAL
Intervention: Glipizide
Number of subjects: 53
Study 3046878 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study 29957723 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapivirine vaginal ring
Number of subjects: 187
Study 27569526 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine learning tool predicting treatment outcomes based on patient-reportable information
Number of subjects: 334
Study 27569526 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine learning tool with top ten predictors
Number of subjects: 334
Study 27569526 — intervention group
Group type: EXPERIMENTAL
Intervention: Amisulpride and olanzapine
Number of subjects: 334
Study 27569526 — intervention group
Group type: EXPERIMENTAL
Intervention: Kaplan-Meier log-rank analyses
Number of subjects: 334
Study 27569526 — intervention group
Group type: EXPERIMENTAL
Intervention: Generalised linear mixed-effects models
Number of subjects: 334
Study 25680824 — intervention group
Group type: EXPERIMENTAL
Intervention: E-learning (17 min duration, using an inflatable manikin)
Number of subjects: 160
Study 25680824 — intervention group
Group type: COMPARATOR
Intervention: Instructor-led training (2 hours)
Number of subjects: 160
Study 23619172 — intervention group
Group type: EXPERIMENTAL
Intervention: Intellivent
Number of subjects: 14
Study 23619172 — intervention group
Group type: COMPARATOR
Intervention: PSV
Number of subjects: 14
Study 20539296 — intervention group
Group type: EXPERIMENTAL
Intervention: WLM
Number of subjects: 48
Study 20539296 — intervention group
Group type: COMPARATOR
Intervention: NW
Number of subjects: 48
Study 20539296 — intervention group
Group type: COMPARATOR
Intervention: OB
Number of subjects: 48
Study 18350395 — intervention group
Group type: EXPERIMENTAL
Intervention: Switch with warning (high and low salience signals)
Number of subjects: 20
Study 18350395 — intervention group
Group type: EXPERIMENTAL
Intervention: Switch without warning (high and low salience signals)
Number of subjects: 20
Study 18350395 — intervention group
Group type: EXPERIMENTAL
Intervention: No switch (high and low salience signals)
Number of subjects: 20
Study 18350395 — intervention group
Group type: EXPERIMENTAL
Intervention: High salience signals
Number of subjects: 20
Study 18350395 — intervention group
Group type: EXPERIMENTAL
Intervention: Low salience signals
Number of subjects: 20
Study 16553052 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative biliary-drainage strategy (standard strategy)
Number of subjects: 0
Study 16553052 — intervention group
Group type: COMPARATOR
Intervention: Early-surgery strategy
Number of subjects: 0
Study 12805393 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate (TPM) 64 mg daily
Number of subjects: 385
Study 12805393 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate (TPM) 96 mg daily
Number of subjects: 385
Study 12805393 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate (TPM) 192 mg daily
Number of subjects: 385
Study 12805393 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate (TPM) 384 mg daily
Number of subjects: 385
Study 12805393 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 385
Study 12805393 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate (TPM)
Number of subjects: 385
Study 10485241 — intervention group
Group type: EXPERIMENTAL
Intervention: Flow rate of 2.0 ml/s
Number of subjects: 125
Study 10485241 — intervention group
Group type: EXPERIMENTAL
Intervention: Flow rate of 3.0 ml/s
Number of subjects: 125
Study 10485241 — intervention group
Group type: EXPERIMENTAL
Intervention: Flow rates of 2.0 ml/s, 3.0 ml/s, and 4.0 ml/s
Number of subjects: 125
Study 10485241 — intervention group
Group type: EXPERIMENTAL
Intervention: Timing of the third helical examination
Number of subjects: 125
Study 10485241 — intervention group
Group type: EXPERIMENTAL
Intervention: Injection of 120 ml contrast medium with a flow rate of 3.0 ml/s
Number of subjects: 125
Study 8561334 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.5% (10 mL)
Number of subjects: 38
Study 8561334 — intervention group
Group type: EXPERIMENTAL
Intervention: Etidocaine 1% (10 mL)
Number of subjects: 38
Study 8561334 — intervention group
Group type: COMPARATOR
Intervention: Saline (control group)
Number of subjects: 38
Study 1759769 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative autologous blood salvage and reinfusion
Number of subjects: 40
Study 1759769 — intervention group
Group type: COMPARATOR
Intervention: Control group (no autologous blood salvage)
Number of subjects: 40
Study 7046900 — intervention group
Group type: EXPERIMENTAL
Intervention: CMFVP
Number of subjects: 312
Study 7046900 — intervention group
Group type: COMPARATOR
Intervention: L-PAM
Number of subjects: 312
Study 31287797 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupressure applied at three acupoints
Number of subjects: 144
Study 31287797 — intervention group
Group type: COMPARATOR
Intervention: Sham acupressure (placebo)
Number of subjects: 144
Study 31287797 — intervention group
Group type: COMPARATOR
Intervention: Routine care only (control)
Number of subjects: 144
Study 28592147 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive and multidisciplinary program conducted in a rehabilitation center
Number of subjects: 159
Study 28592147 — intervention group
Group type: EXPERIMENTAL
Intervention: Less intensive outpatient program conducted by a trained private physiotherapist
Number of subjects: 159
Study 28592147 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed strategy combining the same outpatient program associated with a weekly multidisciplinary intervention
Number of subjects: 159
Study 28592147 — intervention group
Group type: COMPARATOR
Intervention: All treatment strategies
Number of subjects: 159
Study 26071616 — intervention group
Group type: EXPERIMENTAL
Intervention: aCRT
Number of subjects: 478
Study 26071616 — intervention group
Group type: COMPARATOR
Intervention: Echo
Number of subjects: 478
Study 24760536 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone gel
Number of subjects: 25
Study 24760536 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 22804972 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium phosphate (50 mg/kg of fat-free mass per day)
Number of subjects: 20
Study 19225858 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesh-plug tension-free (MPTF) hernia repair
Number of subjects: 106
Study 19225858 — intervention group
Group type: COMPARATOR
Intervention: Open-tension (OT) hernia repair
Number of subjects: 106
Study 17287327 — intervention group
Group type: EXPERIMENTAL
Intervention: Test tampon with apertured film cover
Number of subjects: 105
Study 17287327 — intervention group
Group type: COMPARATOR
Intervention: Reference tampon with nonwoven fleece cover
Number of subjects: 105
Study 17287327 — intervention group
Group type: EXPERIMENTAL
Intervention: Both test and reference tampons
Number of subjects: 105
Study 15067698 — intervention group
Group type: EXPERIMENTAL
Intervention: Melt extrusion
Number of subjects: 0